ULTOMIRIS

उत्पाद अवलोकन

About ULTOMIRIS

ULTOMIRIS is a prescription medication used to treat certain conditions. It contains the active ingredient RAVULIZUMAB, a monoclonal antibody that targets the complement system, specifically the C5 protein. By inhibiting the C5 protein, ULTOMIRIS helps to reduce inflammation and prevent damage to the body's tissues.

Key Benefits & Uses

• Treatment of adult patients with atypical hemolytic uremic syndrome (aHUS) to prevent attacks
• Prevention of acute aHUS attacks in adult and pediatric patients 1 month of age and older
• Treatment of adult patients with primary periodic paralysis (PP) to prevent attacks

Active Ingredient & Action

RAVULIZUMAB, the active ingredient in ULTOMIRIS, works by binding to the C5 protein and preventing it from interacting with its receptors. This action helps to reduce the formation of the membrane attack complex (MAC), which is responsible for cell lysis and tissue damage. By inhibiting the C5 protein, RAVULIZUMAB helps to reduce inflammation and prevent damage to the body's tissues.

Important Notes

ULTOMIRIS is a prescription medication that should only be used under the guidance of a healthcare professional. It is essential to follow the recommended dosing schedule and to report any adverse reactions or concerns to your healthcare provider. Additionally, patients with a history of hypersensitivity reactions to RAVULIZUMAB or other monoclonal antibodies should be closely monitored for signs of anaphylaxis or other severe reactions.